Source: BEFREE

Variant Gene Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs137852593
rs137852593
AR
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.740 GeneticVariation BEFREE R726L substitution in the hormone binding region of androgen receptor was found in 1 prostate cancer family but no previously uncharacterized germline mutations were detected. 14665948

2004
dbSNP: rs137852593
rs137852593
AR
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.740 GeneticVariation BEFREE To estimate the possible involvement of the prostate cancer predisposing AR Arg726Leu germ-line mutation in MBC, this mutation was tested in 117 MBC patients. 12602915

2003
dbSNP: rs137852593
rs137852593
AR
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.740 GeneticVariation BEFREE R726L androgen receptor mutation is uncommon in prostate cancer families in the united states. 12539229

2003
dbSNP: rs137852593
rs137852593
AR
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.740 GeneticVariation BEFREE The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients. 11103816

2000
dbSNP: rs137852593
rs137852593
AR
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 GeneticVariation BEFREE R726L substitution in the hormone binding region of androgen receptor was found in 1 prostate cancer family but no previously uncharacterized germline mutations were detected. 14665948

2004
dbSNP: rs137852593
rs137852593
AR
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 GeneticVariation BEFREE R726L androgen receptor mutation is uncommon in prostate cancer families in the united states. 12539229

2003
dbSNP: rs137852593
rs137852593
AR
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 GeneticVariation BEFREE To estimate the possible involvement of the prostate cancer predisposing AR Arg726Leu germ-line mutation in MBC, this mutation was tested in 117 MBC patients. 12602915

2003
dbSNP: rs137852593
rs137852593
AR
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 GeneticVariation BEFREE The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients. 11103816

2000
dbSNP: rs137852593
rs137852593
AR
CUI: C2931456
Disease: Prostate cancer, familial
Prostate cancer, familial 		0.010 GeneticVariation BEFREE The AR R726L allele does not account for a significant proportion of early-onset and/or familial prostate cancer in the United States. 12539229

2003
dbSNP: rs137852593
rs137852593
AR
CUI: C0238033
Disease: Carcinoma of Male Breast
Carcinoma of Male Breast 		0.010 GeneticVariation BEFREE To estimate the possible involvement of the prostate cancer predisposing AR Arg726Leu germ-line mutation in MBC, this mutation was tested in 117 MBC patients. 12602915

2003
dbSNP: rs137852593
rs137852593
AR
CUI: C0242787
Disease: Malignant neoplasm of male breast
Malignant neoplasm of male breast 		0.010 GeneticVariation BEFREE To estimate the possible involvement of the prostate cancer predisposing AR Arg726Leu germ-line mutation in MBC, this mutation was tested in 117 MBC patients. 12602915

2003
dbSNP: rs137852593
rs137852593
AR
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.010 GeneticVariation BEFREE The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients. 11103816

2000
dbSNP: rs137852593
rs137852593
AR
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.010 GeneticVariation BEFREE The present study indicates that the R726L substitution in the AR may confer an up to 6-fold increased risk of prostate cancer and may contribute to cancer development in up to 2% of Finnish prostate cancer patients. 11103816

2000